Clinical Trial Update: ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for Vorasidenib in combination with a tumor-specific peptide vaccine in recurrent IDH1-mutant lower-grade gliomas; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: Katy Peters, MD, PhD | Conditions: Low Grade Glioma of Brain | Phase 1 | Status: RECRUITING